Atlanta Braves Holdings, Inc. - Series C (BATRK)
Live price chart, market sentiment, and community perspectives for Atlanta Braves Holdings, Inc. - Series C (NASDAQ: BATRK).
Live price chart, market sentiment, and community perspectives for Atlanta Braves Holdings, Inc. - Series C (NASDAQ: BATRK).
On our desk, BATRK is presenting an intriguing setup. Analysts are firmly positioned in the 'Buy' camp with an average price target sitting around $61.20, suggesting double-digit upside from current trading levels near $53.58. Longleaf Partners and other funds have highlighted the ongoing cash flow generation and property value embedded within The Battery Atlanta. However, you cannot ignore the macro valuation headwinds—trailing P/E ratios are negative given recent quarterly losses, and forward multiples are stretched. Market sentiment appreciates the scarcity value of owning a premier MLB asset, but execution on the BravesVision media shift is critical to justify multiple expansion.
Looking at the fundamental risk factors across our institutional coverage, BATRK carries distinct operational vulnerabilities. While Q1 2026 showed a robust revenue bounce to $72M, Q2 faced year-over-year revenue declines due to a lighter home game schedule and regional media transition timing. Furthermore, investors must account for structural cost pressures, notably rising player compensation and heavy outlays tied to launching BravesVision. Looking further ahead, the looming expiration of the MLB collective bargaining agreement in 2026 introduces binary headline risk regarding potential work stoppages that could severely disrupt operations.
As a quant monitoring liquidity and price action, BATRK shows a relatively low 5-year monthly beta of around 0.82, reflecting defensive characteristics typical of entertainment holding assets, yet it has outperformed parts of the broader market with strong YTD gains exceeding 35%. When analyzing valuation metrics, focus heavily on the Enterprise Value relative to its $4.27B EV against an EBITDA base hovering near $39.76M. The high EV/EBITDA multiple indicates that the market is pricing in substantial long-term monetization of both the team and the surrounding real estate assets rather than immediate near-term earnings yield.
Explore plasma cleansing, somatic organ swaps, and BCI.